Press Releases

Summary Toggle Adamas Announces New Employment Inducement Grant

Jul 10, 2020

EMERYVILLE, Calif., July 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 62,500 shares of the company’s common stock, at a
Summary Toggle Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment

Jun 17, 2020

EMERYVILLE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the completion of its evaluation of ADS-5102
Summary Toggle Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes

Jun 4, 2020

EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that its supplemental New Drug Application
Summary Toggle Adamas to Present at Upcoming William Blair Conference

Jun 3, 2020

EMERYVILLE, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F.
Summary Toggle Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson’s disease - expands coverage with reduction of ‘OFF’ time and increased ‘good ON’ time

May 13, 2020

EMERYVILLE, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no.
Summary Toggle Adamas Announces New Employment Inducement Grant

May 8, 2020

EMERYVILLE, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 66,000 shares of the company’s common stock, at a
Summary Toggle Adamas Reports First Quarter 2020 Financial Results

May 7, 2020

First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter 2019 EMERYVILLE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc.
Summary Toggle Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020

Apr 27, 2020

EMERYVILLE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and
Summary Toggle Adamas Announces New Employment Inducement Grant

Apr 10, 2020

EMERYVILLE, Calif., April 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees the option to purchase an aggregate of 86,000 shares of the company’s common stock, at a
Summary Toggle Adamas Announces New Employment Inducement Grant

Mar 6, 2020

EMERYVILLE, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 70,000 shares of the company’s common stock, at a